Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Stryker Corporation — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $95.58, while Stryker Corporation trades at $328.47 (market cap $121.31B). The key difference: Stryker Corporation pays a 1.11% dividend while iShares JPMorgan USD Emerging Markets Bond ETF pays none, and iShares JPMorgan USD Emerging Markets Bond ETF is trading nearer its 52-week high, Stryker Corporation nearer its low. Which is the better fit depends on your goals.
| EMB | SYK | |
|---|---|---|
Sector | Fixed Income | Technology |
52-Week High | $97.74 | $403.53 |
52-Week Low | $91.59 | $282.58 |
Market Cap | — | $121.31B |
Enterprise Value | — | $133.07B |
Dividend Yield | — | 1.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $95.54, down slightly by 0.03% on the day, with a bearish technical signal driven by moving averages. Recent corporate actions include scheduled dividends for 2026, with payouts of $0.41 and $0.40 per share. News highlights focus on emerging market bond risks and Federal Reserve policy impacts, with the ETF showing a 12% total return over the past year but only 1% year-to-date gains as of May 2026.
The outlook for EMB is cautious due to bearish technical indicators and macroeconomic sensitivities. Key risks include emerging market sovereign default exposure and interest rate volatility. Analyst sentiment is mixed, with attention on Fed policy and global bond market dynamics as critical drivers for future performance.
Stryker (SYK) trades at $330.48, up 6.19% with strong analyst support (74% buy ratings) and a $388.44 consensus price target. The stock shows bearish technical signals despite recent earnings beats in Q3 and Q4 2025, offset by a Q1 2026 miss attributed to a temporary cyber disruption. Fundamentals remain solid with 63.83% gross margins and 13.21% net income margin, while the company continues innovation with Mako robotics expansion and new product launches.
The outlook remains positive given maintained full-year guidance and healthy end-market demand. Key risks include cybersecurity vulnerabilities and competitive pressures, but institutional confidence is high with no sell ratings. The current valuation at 36.63 P/E offers potential upside to the price target, supported by robust cash flow generation and dividend consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
